The Food and Drug Administration are probing new data that indicates drugs used to treat prostate cancer could increase the risk of diabetes and heart disease . The drugs, which are used to suppress testosterone, may fuel the growth of prostate cancer tumours . The drugs are also sometimes used to treat women suffering from a specific uterine complaint.
The FDA have gone on record saying that the drugs are not conclusively linked to health problems. However, six preliminary studies show slightly higher rates of diabetes and heart disease .
Doctors are being advised to closely monitor diabetes patients for any sign of either diabetes or heart disease. Specific diabetes drugs under scrutiny include Zoladex, Synarel, and Lupron.
Diabetes drug link to prostate cancer
Tue, 04 May 2010
Recommended links
Diabetes forumDiabetes charities
Healthcare professionals
Diabetes and finance
Diabetes and your retirement plans
The Diet Plate helps to control diabetes
Diabetes drug could reverse fatty liver disease
Roche eye drug could treat diabetes retinopathy
Victoza may be a more effective diabetes drug than Januvia
Lung cancer prevention from diabetes drug
Diabetes drug study positive according to Sanofi
Diabetes drug distribution suspended in Saudi Arabia
Diabetes management system approved by Food and Drug Administration
Food and Drug Administration call for more information on Amylin diabetes drug
Supporters of diabetes drug had financial ties to pharmaceutical company
Diabetes injection Byetta LAR faces Food and Drug Administration decision
GlaxoSmithKline defends diabetes drug Avandia
Patient concern over diabetes drug Avandia
Food and Drug Administration say diabetes patients should not stop taking Avandia
Popular Cholesterol drugs increase diabetes risk
Smell of fish may put patients off diabetes drug
24 hour Diabetes drug Victoza approved for National Health Service use
Diabetes drug could cut body mass index
Weight loss drug alli could reduce dangerous diabetes fat
Type 2 diabetes drug gets Food and Drug Administration approval
Lexicon diabetes drug hits mid-stage trial
Join us